Tang Wei, Xu Hao, Park Edwin J, Philbert Martin A, Kopelman Raoul
Department of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, MI 48109-1055, USA.
Biochem Biophys Res Commun. 2008 May 2;369(2):579-83. doi: 10.1016/j.bbrc.2008.02.066. Epub 2008 Feb 25.
The ability to prevent methylene blue (MB), a photosensitizer, from being reduced by plasma reductases will greatly improve its efficacy in photodynamic therapy (PDT) applications. We have developed a delivery approach for PDT by encapsulating MB using nanoparticle platforms (NPs). The 30-nm polyacrylamide-based NPs provide protection for the embedded MB against reduction by diaphorase enzymes. Furthermore, our data shows the matrix-protected MB efficiently induces photodynamic damage to tumor cells. The unprecedented results demonstrate the significant in vitro photodynamic effectiveness of MB when encapsulated within NPs, which promises to open new opportunities for MB in its in vivo and clinical studies.
防止光敏剂亚甲蓝（MB）被血浆还原酶还原的能力将极大地提高其在光动力疗法（PDT）应用中的疗效。我们通过使用纳米颗粒平台（NPs）封装MB开发了一种用于PDT的递送方法。基于30纳米聚丙烯酰胺的NPs为嵌入的MB提供保护，防止其被黄递酶还原。此外，我们的数据表明，基质保护的MB能有效地诱导对肿瘤细胞的光动力损伤。这些前所未有的结果证明了MB封装在NPs内时具有显著的体外光动力有效性，这有望为MB在体内和临床研究中开辟新的机会。
